White matter hyperintensity on MRI and plasma Aβ42/40 ratio additively increase the risk of cognitive impairment in hypertensive adults.
Adam H de HavenonRebecca F GottesmanJeff D WillamsonNatalia RostRicha SharmaVivian LiLauren LittigEric StulbergGuido J FalconeShyam PrabhakaranAndrea L C SchneiderKevin N ShethNicholas M PajewskiAdam M BrickmanPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
White matter hyperintensity (WMH) and plasma amyloid (Aβ42/40) are additive risk factors for the development of cognitive impairment in the SPRINT MIND trial. Individuals in the high-risk categories of both WMH and Aβ42/40 had a near fivefold increase in risk of cognitive impairment during 4.8 years of follow-up on average. These findings suggest that treatment strategies targeting both vascular health and amyloid burden warrant further research.
Keyphrases
- cognitive impairment
- white matter
- multiple sclerosis
- healthcare
- blood pressure
- public health
- magnetic resonance imaging
- clinical trial
- study protocol
- mental health
- contrast enhanced
- cancer therapy
- health information
- randomized controlled trial
- risk factors
- high intensity
- computed tomography
- magnetic resonance
- resistance training
- double blind